Sellas Positive Topline Data in Lymphoma Cohort in Phase 1 Trial, Supporting Advancement to Phase 2

52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable Survival Benefit -

- Responses Observed Across Dose Levelswith a 14.7% Clinical Response Rate Overall, 35.3% Overall Disease Control Rate, and 36.4% Clinical Response Rate in PTCL Patients -

- Decrease in MCL1 and/or MYC Biomarkers Observed in 100% of Patients in a Dose-Dependent Manner in Once Per Week Administration Regimen -

- Recommended Phase 2 Dose for Lymphoma Patients Established at 100 mg Once Per Week-

- No Off-Target Safety Issues at any Dose Level –

https://www.biospace.com/article/releases/sellas-announces-positive-topline-data-in-lymphoma-cohort-from-sls009-phase-1-dose-escalation-trial-supporting-advancement-to-phase-2-clinical-study-primary-and-secondary-endpoints-met/